Bio
Details

Mr. Howarth (58), most recently served as the Chief Financial Officer of Madrigal Pharmaceuticals, Inc.(Nasdaq: MDGL), a role he held from May 2021 through May 2024. Prior to joining Madrigal, Mr. Howarth was the Chief Operating Officer of Akcea Therapeutics, Inc. (Nasdaq: AKCA) from November of 2019 through the acquisition (in October of 2020) by Ionis Pharmaceuticals, Inc. until December 2020. Before Akcea, Mr. Howarth was the President (from January to November of 2019) and Chief Financial Officer (from September of 2015 to November of 2019) at Lycera Corp. Mr. Howarth has also held roles as Chief Financial Officer and Chief Business Officer at moksha8 Pharmaceuticals, Inc., from May 2007 to September of 2015, and prior to this served as Chief Business Officer at Vitae Pharmaceuticals, Inc. and Head of Venture Partnerships at GlaxoSmithKline plc. Mr.Howarth earned a Bachelor of Applied Science in Biochemistry from the University of Bath and qualified as a Chartered Accountant in the UK.